Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease

Authors not listed

Merck Sharp & Dohme LLC · 2006

Abstract

The purpose of this study is to test the efficacy and safety of an investigational medication for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication or placebo for 28 days. Tests of memory, concentration will be included. Safety will be monitored using routine clinical and laboratory tests.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2006). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease. <em>Merck Sharp & Dohme LLC</em>. https://clinicaltrials.gov/study/NCT00420420
Vancouver
Anonymous. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease. Merck Sharp & Dohme LLC. 2006.
BibTeX
@misc{anon2006ARando, title = {A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease}, author = {Anonymous}, journal = {Merck Sharp & Dohme LLC}, year = {2006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings